Long-Term Hydromethylthionine Treatment Is Associated with Delayed Clinical Onset and Slowing of Cerebral Atrophy in a Pre-Symptomatic P301S MAPT Mutation Carrier (2021)

Peer-Reviewed Study · Bentham P, Staff RT, Schelter BO, Shiells H, Harrington CR, et al. · 2021

Bentham P et al., 2021: Single-patient report of five years of hydromethylthionine in an asymptomatic carrier of the P301S MAPT mutation causing inherited frontotemporal dementia, reporting slower frontal and temporal atrophy and no clinical onset.

During the period of treatment, the rates of progression of cerebral atrophy were reduced by 61%-66% in frontal and temporal lobes, and the patient remained clinically asymptomatic.

abstract

Bentham P et al., 2021: Single-patient report of five years of hydromethylthionine in an asymptomatic carrier of the P301S MAPT mutation causing inherited frontotemporal dementia, reporting slower frontal and temporal atrophy and no clinical onset. Study type: single case report (n=1), open-label, no control group – the authors' own framing is observational. Country: not stated in abstract (authors are UK-based TauRx collaborators). Dose/schedule: hydromethylthionine over a 5-year period, begun at the family's mean age of onset; dose not stated in abstract. Comparator: historical rates of atrophy in affected family members / pre-treatment trajectory, not a concurrent control. Funder/conflicts: TauRx-affiliated authors; declared in the paper. Weakest possible design; cannot establish efficacy. Study type: case report.